| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
DURHAM, N.C.—Despite the wealth of in silico designs and in vitro assays that scientists use to identify new therapeutic compounds, a new drug often fails because of side effects noted during in vivo screening. Thus, while in vivo screening can be expensive, it is irreplaceable—unless, of course, someone can find a way to mimic in vivo metabolism in vitro. With this in mind, researchers at ADMET Technologies and the University of North Carolina recently created an artificial liver.
 
As they described recently in a poster, the researchers developed a multicoaxial bioreactor (MCB) that is based on 2-D sandwich cell culturing techniques developed decades ago. In this case, however, the hepatocytes grow in a three-dimensional matrix that more closely mimics the structure and dimensions of a human liver. Thus, when drugs are introduced to the MCB, it is thought their behavior more closely follows physiological pharmacokinetics.
 
The scientists isolated liver cells, which they introduced to a 50:50 mixture of collagen type 1 and Matrigel, allowing the combination to gel in the MCB. They then used NMR spectrometry to monitor metabolic activity and noted that the MCB cells behaved as expected and that enzyme levels and general cell health remained constant over an extended period of time. And in each case, the cells in the 3-D matrix performed more naturally than those in a 2-D sandwich.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue